A Scottish Biotech Just Secured $46M to Tackle a Silent Kidney Disease

Jan de Vries · 2026-08-07

Biotech funding rounds can feel like a dime a dozen these days, but every once in a while, one deserves a closer look. That's exactly the case with Glasgow-based Mironid, which just closed a hefty $46 million Series B round. The money isn't just for show—it's earmarked to push a promising new treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through the grueling clinical development process. If you've never heard of ADPKD, you're not alone. But the numbers are stark. It's the most common hereditary kidney disorder, affecting more than 12 million people globally. Half of those patients will face kidney failure by age 60. That's a ticking clock for millions, and current treatment options leave a lot to be desired. ### Who's Backing the Play? The round was led by the Scottish National Investment Bank, with heavy hitters like Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde also chipping in. When a syndicate like this aligns, it sends a clear signal to the market that the science has legs. Neil Wilkie, Mironid's CEO, didn't mince words about what the validation means. "Securing funding from such a high-calibre syndicate is a strong validator of our approach," he said. The cash infusion will let the company move its lead candidate forward, edging closer to what could be a sea change in how rare kidney diseases are treated. ### The Science: Chasing a Different Target Mironid spun out of the University of Strathclyde and Heriot-Watt University back in 2015, building on over three decades of research into PDE biology by Professor Miles Houslay. The company's focus is on degenerative and rare genetic kidney diseases, but also major inflammatory conditions and cancer. Here's where things get interesting. Mironid's lead candidate is a "LoAc" small molecule that takes a different tack than existing therapies. Instead of just managing symptoms, it targets cyclic AMP (cAMP) directly—a cellular signal that's active at every stage of the disease, from the very first cyst to end-stage failure. Why does that matter? Because cAMP drives both cell proliferation and fluid secretion inside those cysts. By going after this root mechanism, Mironid aims to prevent new cysts from forming and halt the growth of existing ones. Preclinical data so far shows significant efficacy, including reductions in cyst number and kidney volume, with a favorable safety profile. ### A More Durable Option? The promise here is a treatment that could offer better durability and fewer side effects compared to what's currently on the market. That's a big deal for patients who are often juggling a cocktail of medications with rough side effects. Beyond ADPKD, Mironid's pipeline is also targeting phosphodiesterase 4 (PDE4) enzymes, which play a key role in disease progression pathways. It's a research-and-development-led model, funded through venture capital and strategic investment, with the long-term goal of moving from preclinical trials to commercialization. ### Scotland's Biotech Moment Paul Callaghan, Investment Director at the Scottish National Investment Bank, framed this as a win for the whole ecosystem. "Mironid exemplifies Scotland's growing reputation for biotech innovation," he said, noting the goal of translating world-class research into clinical progress and patient benefit. This Series B follows an earlier Series A extension, bringing Mironid's total funding since inception to roughly $46.7 million. It's a solid war chest for a company at this stage. ### The Bottom Line For anyone watching the rare disease space, this is a name to keep on your radar. The science is compelling, the investors are serious, and the unmet medical need is enormous. If Mironid's approach holds up in clinical trials, it could genuinely change the treatment landscape for ADPKD patients—and maybe beyond.